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reproduction in any medium, provided the original author and source are credited.SUMMARYTauopathies represent a group of neurodegenerative disorders characterized by the accumulation of pathological TAU protein in brains.
We report a human neuronal model of tauopathy derived from induced pluripotent stem cells (iPSCs) carrying a TAU-A152T mutation.
Using zinc-finger nuclease-mediated gene editing, we generated two isogenic iPSC lines: one with the mutation corrected, and another
with the homozygous mutation engineered. The A152T mutation increased TAU fragmentation and phosphorylation, leading to
neurodegeneration and especially axonal degeneration. These cellular phenotypes were consistent with those observed in a patient
with TAU-A152T. Upon mutation correction, normal neuronal and axonal morphologies were restored, accompanied by decreases in
TAU fragmentation and phosphorylation, whereas the severity of tauopathy was intensified in neurons with the homozygousmutation.
These isogenic TAU-iPSC lines represent a critical advancement toward the accuratemodeling andmechanistic study of tauopathies with
human neurons and will be invaluable for drug-screening efforts and future cell-based therapies.INTRODUCTION
Tauopathies are a group of neurodegenerative disorders
characterized by the accumulation and aggregation of
the pathological TAU protein in human brains (Hutton,
2000; Lee et al., 2001; Mandelkow and Mandelkow,
2012; Vossel and Miller, 2008). TAU, encoded by the
MAPT gene on chromosome 17, is a microtubule binding
protein that is highly expressed in neurons and predomi-
nantly located in neuronal axons (Goedert et al., 1989;
Kosik et al., 1989; Morris et al., 2011; Neve et al., 1986).
Hyperphosphorylation and aggregation of TAU cause
neurofibrillary pathologies, including tangles and neuro-
pil threads that are often seen in brains of patients with
Alzheimer’s disease (AD) (Hutton, 2000; Kosik et al.,
1986; Lee et al., 2001; Mandelkow and Mandelkow,
2012; Vossel andMiller, 2008). Tauopathies are also typical
of other neurodegenerative disorders, including fronto-
temporal dementia (FTD) and progressive supranuclear
palsy (PSP) (Hutton, 2000; Lee et al., 2001; Mandelkow
and Mandelkow, 2012; Vossel and Miller, 2008). Most
FTD and PSP cases are sporadic, but a minority are familial
(Weder et al., 2007). FTD and PSP syndromes can be
caused by mutations in the MAPT gene that result in226 Stem Cell Reports j Vol. 1 j 226–234 j September 10, 2013 j ª2013 Theabnormal TAU phosphorylation and aggregation, leading
to neurodegeneration.
Transgenic murine models of tauopathies have revealed
fundamental insights into the disease (Lee et al., 2001;
Mandelkow and Mandelkow, 2012), but their value as
predictive preclinical models is unknown. In fact, many
candidate drugs successful in rodent models of neuro-
degenerative diseases have failed in humans (Ashe and
Zahs, 2010; Huang and Mucke, 2012). Thus, new human-
ized disease models, such as mutation- and patient-specific
induced pluripotent stem cells (iPSCs), are urgently needed
for further development of therapeutic strategies for
tauopathies.
Human iPSCs are a highly promising approach for inves-
tigating cellular properties of traditionally challenging
neurodegenerative disorders (HD iPSC Consortium, 2012;
Israel et al., 2012; Kondo et al., 2013; Park et al., 2008;
Yamanaka, 2009). Because postmortem tissue represents
late-stage disease, modeling tauopathy onset and progres-
sion are problematic with autopsy samples alone. iPSC-
derived neurons grown in culture allow for the detection
of specific molecular and temporal signatures from muta-
tion-carrying patients, thereby improving our understand-
ing of the pathogenesis of tauopathies.Authors
FokI  
Nuclease 
G CC CCC TGT AA A ACA T G A T A 
CGG G G G A C A T TT T G T A C T A T 
ZF5 ZF4 ZF3 
ZF6 ZF7 ZF8 
FokI  
Nuclease 
G A G 
C T C 
ZF2 
T C A 
A G T
ZF9 
152T
152A
152A
MAPT
152T
Allele
Donor Targeting
Vector
Corrected
MAPT 
152A Allele
C C A 
GGT
ZF10 
GG 
CC C 
ZF1 
G
T TAC 
A A T G 
15
2A
/T-
HD
F
15
2A
/T-
iP
SC
15
2A
/A
-H
DF
15
2A
/T-
iP
SC
15
2A
/A
-iP
SC
15
2T
/T-
iP
SC
15
2A
/T-
iP
SC
15
2A
/T-
iP
SC
15
2A
/A
-H
DF
G/A G/G G/A
A/A
152A/T 152A/A 152A/T 152T/T
Phase Oct4 Sox2
15
2A
/T
15
2A
/A
15
2T
/T
J
A
CB
D E F
G H I
K L
Figure 1. Generation of Isogenic Human TAU-A152T-iPSC Lines
with ZFN-Mediated Gene-Editing Technology
(A) Schematic of ZFN-mediated correction of the TAU-A152T
mutation.
(B) Screening of iPSCs with genetic correction of the TAU-A152T
mutation by HphI restriction digestion of a TAU PCR product from
genomic DNA (gDNA) of different iPSC clones. Sequencing of the
gDNA from the isogenic TAU-152A/A-iPSCs confirmed correction of
the nucleotide from A to G at the original mutation site (red
arrows). For more information, see Figure S1.
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Genetic Correction of Tauopathy in Human iPSCsOne limitation of using iPSCs is the inability to carry out
studies under genetically defined conditions, leading to
increased experimental variability. To overcome these
obstacles, we used a zinc-finger-nuclease (ZFN)-mediated
gene-editing technique (An et al., 2012; Corti et al., 2012;
Li et al., 2012; Soldner et al., 2011) to generate isogenic
human iPSC lines from an individual carrying a TAU-
A152T mutation. We demonstrate that isogenic TAU-iPSCs
are not only useful for modeling tauopathies, but also for
identifying unknown molecular mechanisms underlying
the disease-causing mutations.RESULTS
Generation of iPSCs from an Individual
with a TAU-A152T Mutation
Wegenerated iPSCs from an individual carrying a heterozy-
gous TAU-A152T mutation (Coppola et al., 2012; Kara
et al., 2012; Kovacs et al., 2011) using a protocol published
previously (Takahashi et al., 2007; Takahashi and Yama-
naka, 2006). The TAU-152A/T-iPSCs had characteristics
similar to embryonic stem (ES) cells, including their ES
cell-like morphology (Figure 1D) and positive staining for
ES cell markers (Figures 1E and 1F; Figures S1B–S1E avail-
able online). DNA sequencing confirmed a heterozygous
TAU-A152T mutation (Figure 1B), and chromosomal anal-
ysis revealed a normal karyotype (Figure 2A). The TAU-
152A/T-iPSCs formed teratomas in immunodeficient mice
(Figures S1N–S1P), confirming their pluripotency.
Generation of Isogenic TAU-A152T-iPSC Lines
We used ZFN-mediated gene-editing technology to
generate isogenic TAU-A152T-iPSC lines (Hockemeyer
et al., 2009; Miller et al., 2007; Soldner et al., 2011). The
ZFN was designed to target 30 base pairs upstream of
the A152T mutation on the MAPT gene (Figure 1A). We
also used a 1,500 bp linear donor DNA fragment carrying
the wild-type nucleotide sequence at position 152 as a
repair template for homologous recombination (Figure 1A).
Alternatively, a donor DNA fragment with a TAU-A152T
mutation could be used to generate a homozygous TAU-
A152T mutation. To obtain ‘‘scarless’’ genome editing,(C) Screening of iPSCs with engineered homozygous TAU-A152T
mutation by HphI restriction digestion of a TAU PCR product from
gDNA of different iPSC clones. Sequencing of the gDNA from the
isogenic TAU-152T/T-iPSCs confirmed the change in nucleotide
from G to A to generate a homozygous mutation (red arrows). For
more information, see Figure S1.
(D–L) Isogenic TAU-A152T-iPSCs demonstrated similar ES cell
morphology (D, G, and J) and stained positive for pluripotency
markers Oct4 (E, H, and K) and Sox2 (F, I, and L).
Scale bars represent 50 mm. See also Figure S1.
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Figure 2. Characterization of the Isogenic TAU-A152T-iPSC Lines
(A–C) Karyotype and G-band analysis confirmed a normal 46, XY karyotype in all three isogenic TAU-A152T-iPSC lines.
(D–F) Global gene expression profiling demonstrated very few variations among all three isogenic TAU-A152T-iPSC lines.
(G–K) All three isogenic TAU-A152T-iPSC lines generated neurospheres at similar levels and of comparable sizes.
(L–N) Stable NSCs expressing the neural precursor markers Sox2 (green) and Nestin (red) could be generated equally well from all three
isogenic TAU-A152T-iPSC lines.
Values are mean ± SD. Scale bars represent 100 mm (G–I) and 50 mm (L–N).
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Genetic Correction of Tauopathy in Human iPSCsthe donor DNA fragment contained no selection marker or
excisable sequence. After nucleofection of the TAU-152-
ZFN and the donor DNA fragment into 2 3 106 TAU-
152A/T-iPSCs (Fong et al., 2011), the cells were allowed to
recover for 2 days and then were plated in a single-cell
format in 96-well plates for 7–14 days.
Inspection of the DNA sequence of the TAU PCR product
revealed two restriction cleavage sites for HphI on the wild-
type allele and three sites on themutant allele (Figure S1A).
After screening 107 clones, a corrected clone was identified
(Figure 1B, 152A/A-iPSC). From screening an additional 86
clones, we also found a clone containing a homozygous
version of the TAU-A152T mutation, where the mutation
was present on both alleles (Figure 1C, 152T/T-iPSC).
DNA sequencing confirmed the correction or homozygous
mutation of TAU-A152T in the isogenic iPSC lines (Figures
1B and 1C). The overall efficiency of TAU-ZFN-mediated
gene editing was 1%1.5%.
Isogenic TAU-A152T-iPSC Lines Have Similar Genetic
and Neural Stem Cell Differentiation Properties
Both isogenic TAU-152A/A-iPSC and TAU-152T/T-iPSC
lines exhibited similar ES cell morphology to the parental
TAU-152A/T-iPSC line and stained positive for pluripo-
tency markers as seen in the parental iPSC line (Figures
1D–1L and S1B–S1M). Furthermore, the newly generated
isogenic iPSC lines had a similar ability as the parental
iPSC line to form teratomas in immunodeficient mice
(Figures S1N–S1V), suggesting similar pluripotency among
all three iPSC lines.
Karyotyping analysis showed that all three isogenic iPSC
lines had a normal 46, XY karyotype (Figures 2A–2C).
Global gene expression profiling of all three lines showed
very few differences in gene expression patterns (Figures
2D–2F). Importantly, all three isogenic iPSC lines had
similar abilities to generate neurospheres (Figures 2G–2K)
and neural stem cells positive for Sox2 and Nestin (Figures
2L–2N).
Genetic Correction of TAU-A152T Mutation Abolishes
and Homozygous TAU-A152T Mutation Intensifies
Tauopathy Phenotypes
Upon neuronal differentiation of the parental TAU-152A/
T-iPSCs (Chambers et al., 2009; Hu and Zhang, 2009;
Ring et al., 2012), immunocytochemical analysis of TAU
revealed unhealthy looking neurons with punctate TAU
staining in neuronal processes (Figure 3E). Their neurites
were short and tapering and appeared to bulge and
constrict with odd bends and breaks (Figure 3E). MAP2
immunostaining confirmedmild degeneration of neuronal
processes (Figure 3B). Genetic correction of themutation in
the isogenic TAU-152A/A-iPSCs abolished the neurodegen-
erative phenotype, leading to the generation of healthyStem Cell Rlooking neurons with smooth TAU and MAP2 staining
(Figures 3A and 3D). In sharp contrast, the isogenic homo-
zygous TAU-152T/T-iPSCs generated neurons with severe
degeneration and a much lower survival of neurons, as
indicated by MAP2 staining (Figure 3C), and much more
punctate TAU staining in neuronal processes (Figure 3F).
Quantitatively, there was a gene-dose-dependent effect of
the TAU-A152T mutation on neurodegeneration as evi-
denced by abnormal TAU staining (Figure S2A). High-
magnification images revealed severe axonal degeneration
and fragmentation of neurons derived from TAU-152T/
T-iPSCs (Figure 3H), which was completely rescued by
correcting the mutation in the isogenic TAU-152A/A-iPSCs
(Figure 3G). Neurodegeneration was also observed in a
subclone of TAU-152T/T-iPSCs (152T/T-2), as evidenced
by abnormal TAU staining (Figure S2B). Low-density
neuronal culture and double immunostaining for TAU
and MAP2 revealed mislocalization of TAU-A152T to the
somatodendritic domains in TAU-152T/T-iPSC-derived
neurons (Figures S2E and S2F).
AT8-positive phosphorylated TAU (p-TAU) was found in
some neurons derived from TAU-152A/T-iPSCs, with a pre-
dominant and punctate location in axons (Figure 3J).
Again, genetic correction of the mutation abolished
p-TAU accumulation (Figure 3I), whereas the homozygous
mutation exacerbated p-TAU accumulation in both axons
and cell soma (Figures 3K and 3L). Themutation-related in-
crease in p-TAU was also observed in a subclone of TAU-
152T/T-iPSC-derived neurons (Figure S2C). Strikingly, the
numbers of p-TAU-positive neurons increased in a TAU-
A152T gene-dose-dependent manner (Figure 3M). Accu-
mulation of p-TAU was restricted to neurons as there was
no p-TAU in GFAP-positive astrocytes (Figure S2G). West-
ern blotting analysis confirmed the presence of high levels
of p-TAU in neurons derived from TAU-152A/T-iPSCs or
TAU-152T/T-iPSCs, which was dramatically decreased
in neurons derived from TAU-152A/A-iPSCs (Figures 4L
and 4M).
Genetic Correction of TAU-A152T Mutation
Eliminates and Homozygous TAU-A152T Mutation
Intensifies the Generation of Pathological TAU
Fragments in Neurons
We observed a greater degree of TAU fragmentation, as
determined by western blotting using the antibody
TAU-5, in neurons derived from TAU-152A/T-iPSCs than
those derived from unrelated control iPSCs without the
mutation (Figures 4A and 4B). More TAU fragmentation
was also observed in brain samples from a patient with
PSP carrying the TAU-A152T mutation than in those from
a control subject without the variant (Figure 4C, arrows).
Importantly, the mutation-related increase in TAU frag-
mentation in human iPSC-derived neurons was confirmedeports j Vol. 1 j 226–234 j September 10, 2013 j ª2013 The Authors 229
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Figure 3. Genetic Correction of TAU-A152T Mutation Abolishes and Homozygous TAU-A152T Mutation Intensifies Tauopathy
Phenotypes in iPSC-Derived Neurons as Determined by Immunocytochemistry
(A–F) Mild neurodegeneration and accumulation of punctate TAU were found in neurons derived from TAU-152A/T-iPSCs (B and E), which
were abolished in the mutation-corrected TAU-152A/A-iPSC-derived neurons (A and D) and intensified in homozygous TAU-152T/T-iPSC-
derived neurons (C and F).
(G and H) High magnification of TAU-152T/T-iPSC-derived neurons showed severe axonal degeneration with the accumulation of punctate
TAU (H), which was completely rescued by genetic correction of the mutation in TAU-152A/A-iPSC-derived neurons (G).
(I–L)AT8-positivephosphorylated TAU (p-TAU)was found in the axons of someneurons fromTAU-152A/T-iPSCs (J, green). Thisphenotypewas
intensified in the axons and cell soma of neurons derived from TAU-152T/T-iPSCs (K and L, green). Correction of the mutation eliminates the
phenotype as evidencedby little to nop-TAU inneuronsderived fromTAU-152A/A-iPSCs (I).All neuronswere also costained for total TAU (red).
(legend continued on next page)
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Figure 4. Genetic Correction of TAU-A152T Mutation Abolishes and Homozygous TAU-A152T Mutation Intensifies Tauopathy
Phenotypes in iPSC-Derived Neurons as Determined by Western Blotting
(A and B) Western blotting with the TAU-5 antibody revealed more TAU fragmentation in neurons derived from the parental TAU-152A/
T-iPSCs than in neurons derived from control iPSCs without the mutation (A). Quantification of TAU bands showed a significantly greater
amount of total fragments of TAU in TAU-152A/T-iPSC-derived neurons than in the control iPSC-derived neurons (B).
(C) Western blotting with the TAU-5 antibody also revealed increased fragmentation of the TAU protein (arrows) in the brain lysate of a
patient with PSP carrying the TAU-A152T mutation.
(D–I) Western blotting with an antibody against the central part (D and E, TAU-5), the N terminus (F and G, TAU-A12), or the C terminus (H
and I, TAU-C17) of the TAU protein confirmed the increases in TAU fragmentation in neurons derived from TAU-152A/T-iPSCs and
TAU-152T/T-iPSCs. The numbers and amounts of TAU fragmentations were dramatically less upon genetic correction of the mutation.
(J and K) A mutant gene-dose-dependent increase of caspase-cleaved TAU (TAU-C3) was observed in neurons derived from the three
isogenic TAU-152A/T-iPSC lines.
(L and M) Higher levels of AT8-positive p-TAU at two molecular masses (>250 and74 kDa) were found in neurons derived from TAU-152A/
T-iPSCs and TAU-152T/T-iPSCs than in neurons derived from TAU-152A/A-iPSCs.
All TAU band quantifications were normalized to total TAU. Values are mean ± SD. *p% 0.05, **p% 0.01.
Stem Cell Reports
Genetic Correction of Tauopathy in Human iPSCsby western blotting with three different TAU antibodies
(TAU-5, TAU-A12, and TAU-C17 that recognize the central
core, N terminus, and C terminus of the protein, respec-(M) Quantification of AT8-positive neurons derived from the isogenic
(N–P) Caspase-cleaved TAU (C3) was found in the axons of neurons de
derived from TAU-152T/T-iPSCs (P), but not in neurons derived from
(Q) Quantification of C3-positive neurons derived from the isogenic T
(R–U) Caspase-cleaved TAU (C3, green) and p-TAU (red) were also fo
carrying the TAU-A152T mutation.
Values are mean ± SD. Scale bars represent 30 mm (A–F, I–L, and N–P
See also Figure S2.
Stem Cell Rtively) (Carmel et al., 1996; Porzig et al., 2007) and was
decreased dramatically upon genetic correction of the mu-
tation (Figures 4D–4I). The mutation-related increase inTAU-A152T-iPSC lines.
rived from TAU-152A/T-iPSCs (O), which was intensified in neurons
TAU-152A/A-iPSCs (N).
AU-A152T-iPSC lines.
und in the axons and cell soma of neurons from a patient with PSP
), 5 mm (G and H), and 10 mm (R–U).
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Genetic Correction of Tauopathy in Human iPSCsTAU fragmentationwas confirmed inneurons derived from
a subclone of TAU-152T/T-iPSCs (Figure 4D, 152T/T-2).
Most strikingly, there was a mutant gene-dose-depen-
dent increase in caspase-cleaved TAU fragments, as deter-
mined by the caspase-cleaved TAU-specific antibody C3
(Gamblin et al., 2003; Guillozet-Bongaarts et al., 2005), in
neurons derived from the isogenic TAU-A152T-iPSCs
(Figures 4J and 4K). In line with this observation, immuno-
staining with the TAU-C3 antibody revealed the accumula-
tion of caspase-cleaved TAU in axons of neurons derived
from TAU-152A/T-iPSCs and TAU-152T/T-iPSCs (Figures
3O and 3P) but not in those of neurons derived from
TAU-152A/A-iPSCs (Figure 3N). Themutation-related accu-
mulation of caspase-cleaved TAU was also observed in
neurons derived from a subclone of TAU-152T/T-iPSCs
(Figure S2D). The numbers of caspase-cleaved TAU-positive
neurons increased in a mutant gene-dose-dependent
manner (Figure 3Q). We observed no caspase-cleaved TAU
in GFAP-positive astrocytes (Figure S2H). Likewise, cas-
pase-cleaved TAU also accumulated in neuronal soma and
axons in the patient with PSP carrying the TAU-A152T
mutation (Figures 3R–3U).Genetic Correction of TAU-A152T Eliminates the
Detrimental Effects of the Mutation on Different
Subtypes of Neurons
We then determined the effects of the TAU-A152T muta-
tion on different subtypes of neurons, including tyrosine-
hydroxylase (TH)-positive dopaminergic neurons, T-box
brain 1 (TBR1)-positive glutamatergic excitatory neurons
(Hevner et al., 2001), and gamma-aminobutyric-acid
(GABA)-positive inhibitory neurons. Strikingly, very low
percentages of dopaminergic neurons were found in
neuronal cultures from TAU-152A/T-iPSCs and TAU-
152T/T-iPSCs (Figures S2J–S2L). Genetic correction of the
mutation increased the percentages of dopaminergic
neurons by 4- to 8-fold (Figures S2I–S2L), suggesting that
dopaminergic neurons are especially vulnerable to TAU-
A152T-induced neurotoxicity. Interestingly, the percent-
ages of glutamatergic and GABAergic neurons were
not significantly altered by the mutation (Figures S2M–
S2T). However, many glutamatergic (Figure S2V) and
GABAergic (Figure S2X) neurons had abnormal morphol-
ogies, including neurite fragmentation/degeneration,
which were also eliminated by genetic correction of the
mutation (Figures S2U and S2W).DISCUSSION
By combining the iPSC and ZFN-mediated gene-editing
techniques, we generated ‘‘scarless’’ isogenic human iPSC
lines carrying wild-type TAU or a heterozygous or homozy-232 Stem Cell Reports j Vol. 1 j 226–234 j September 10, 2013 j ª2013 Thegous TAU-A152Tmutation. The use of genetically matched
isogenic iPSC lines, with three gene doses of the mutation
(zero, one, and two copies) on an identical genetic
background, eliminates potential subject-to-subject and
line-to-line variations of iPSCs and helps draw a clear
conclusion regarding mutation-specific phenotypes. The
isogenic TAU-iPSC lines generated in this study will be
invaluable for further mechanistic studies of tauopathies
and for related drug-screening efforts.
Before the TAU-A152T mutation was identified in
humans, it was widely accepted that mutations of TAU
cause FTD and PSP, but not AD (Huang and Mucke,
2012). The TAU-A152T mutation is the first to show the
association of a TAU mutation with increased risks for
FTD, PSP, and AD (Coppola et al., 2012). Thus, the tauop-
athy model of human iPSCs, and the related molecular
mechanisms identified in this study, should be applicable
to all three tauopathy-related diseases for further mecha-
nistic studies and drug screening.
Although modeling neurodegenerative diseases with
iPSCs has been reported (HD iPSC Consortium, 2012; Israel
et al., 2012; Kondo et al., 2013; Park et al., 2008; Yamanaka,
2009), they typically recapitulate phenotypes reported in
cell cultures or animal studies. Our study, however, iden-
tifies an unknown molecular mechanism underlying a
disease-causing TAU mutation using isogenic iPSCs. A
previous study reported that the TAU-A152T mutation
increased soluble TAU oligomers and decreased microtu-
bule-binding affinity of TAU in cell cultures and test tubes
(Coppola et al., 2012). We demonstrate in iPSC-derived
humanneurons that thismutation predisposes TAU to pro-
teolysis by caspase and other proteases, leading to tauop-
athy, axonal degeneration, and other related pathologies.
We further demonstrate that correction of the mutation
eliminates TAU proteolysis, indicating the specific effect
of the mutation on TAU proteolysis. Our work therefore
directly demonstrates that iPSCs, especially isogenic iPSCs,
are a powerful tool not only for disease modeling but also
for studies of disease mechanisms. Interestingly, dopa-
minergic neurons are especially vulnerable to TAU-
A152T-induced neurotoxicity, which is in line with the
observation that tauopathy in PSP is associated with exces-
sive dopaminergic neuron loss (Murphy et al., 2008). The
underlying mechanism remains to be determined.EXPERIMENTAL PROCEDURES
Reprogramming Human Dermal Fibroblasts into
iPSCs
Fibroblasts were obtained from an individual carrying the TAU-
A152T mutation in the MAPT gene. iPSCs were generated from
early passages of fibroblasts by a retroviral reprogramming strategy
with four factors (Oct4, Sox2, Klf4, and c-Myc) (Takahashi et al.,Authors
Stem Cell Reports
Genetic Correction of Tauopathy in Human iPSCs2007; Takahashi and Yamanaka, 2006). The animal procedure for
testing teratoma formation was approved by the Gladstone Insti-
tutes and the University of California, San Francisco.
Preparation of ZFNs and Generation of Isogenic iPSC
Lines
A specific pair of five-finger ZFNs engineered to target a region
30 bp upstream of the A152T mutation site was prepared by
Sigma. The ZFNs bound (uppercase) and cut (lowercase) the
following sequence on the MAPT gene: CCCCTCTATCATGTTt
catttACAGGGGGCTGATGG. Isogenic TAU-A152T-iPSC lines
were generated using this ZFN pair and a donor construct (An
et al., 2012; Corti et al., 2012; Li et al., 2012; Soldner et al., 2011).
Neuronal Differentiation of iPSCs
iPSCs were differentiated into neurons following a modified
version of published protocols (Chambers et al., 2009; Hu and
Zhang, 2009; Ring et al., 2012). Tauopathies were characterized
by western blotting and immunocytochemistry with different
TAU antibodies.
Human Neuropathology
Tauopathies were characterized by western blotting and immuno-
cytochemistry with different TAU antibodies on postmortembrain
tissues from a 56-year-old woman with clinical and pathological
PSP who carried the MAPT A152T variant and a 76-year-old man
who died of prostate cancer without cognitive complaints.
Statistical Analyses
Values are expressed as mean ± SD. Differences between means
were assessed by t test or analysis of variance (ANOVA). p < 0.05
was considered statistically significant.
Detailed methods, including isogenic iPSC generation and char-
acterization, neuronal differentiation, immunostaining, western
blotting, and tauopathy analyses can be found in the Supple-
mental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one table and can be found with this
article online at http://dx.doi.org/10.1016/j.stemcr.2013.08.001.
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